
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of November 2021

Commission File Number: 001-39328

Genetron Holdings Limited

(Exact Name of Registrant as Specified in Its Charter)

**1-2/F, Building 11, Zone 1
No.8 Life Science Parkway
Changping District, Beijing, 102206
People's Republic of China
+86 10 5090-7500
(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Genetron Holdings Limited

By: /s/ Sizhen Wang

Name: Sizhen Wang

Title: Chief Executive Officer

Date: November 30, 2021

EXHIBIT INDEX

| <u>Exhibit</u> | <u>Description</u> |
|----------------|---|
| 99.1 | Press Release titled “Genetron Health Announces Co-Development Agreement with AstraZeneca R&D China for Personalized MRD Tests for Solid Tumors in China” |
| 99.2 | Press Release titled “Genetron Health Reports Third Quarter 2021 Unaudited Financial Results” |

**Genetron Health Announces Co-Development Agreement with AstraZeneca R&D China for
Personalized MRD Tests for Solid Tumors in China**

Collaboration highlights the value of MRD solid tumor data generated by Genetron's Mutation Capsule platform, and further accelerates product development

BEIJING, November 30, 2021 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has signed a collaboration agreement with AstraZeneca R&D China (“AstraZeneca – LSE/STO/Nasdaq: AZN”) for the joint development in China of next-generation sequencing (NGS)-based tumor-informed (personalized) minimal residual disease (MRD) tests for various solid tumor types. AstraZeneca plans to incorporate the co-developed tests for China-specific studies.

Under the agreement, the companies will jointly invest capital for this collaboration, and will work together to develop and validate the personalized, solid tumor MRD assays for cancer monitoring and recurrence in China. These assays will be developed based on the genetic analysis of the primary tumor from individual patients at the beginning of treatment. A joint committee will be established to oversee the product development.

For solid tumor clinical trials in China that incorporate the use of NGS-based personalized MRD tests, AstraZeneca plans to incorporate the aforementioned co-developed MRD test in China-specific studies, subject to fulfillment of individual study criteria. Upon both companies further agreement, the scope of the agreement may also be expanded to include IVD registration and commercialization. This is an exclusive, multi-year collaboration agreement between both parties, with exclusivity contingent on certain requirements.

“We are happy to work with Genetron Health with the aim to collaboratively develop and potentially commercialize an NGS-based MRD assay to help in directing the right treatments to the right patients. We look forward to joining forces and leveraging both companies’ expertise, in the hope of bringing an innovative and effective diagnostic to benefit more cancer patients in China,” said Jing He, Senior Vice President, Head of R&D China, AstraZeneca.

“We are thrilled to partner with a leading oncology global company such as AstraZeneca, and we are proud that this partnership demonstrates the value of the initial solid tumor MRD data that we have generated so far from Genetron’s Mutation Capsule platform, the proprietary technology that we developed in-house,” said Sizhen Wang, co-founder and CEO of Genetron Health. “The agreement represents the first step of a long-term collaboration. Our goal is to develop a world-class MRD product, by combining AstraZeneca’s global leading position in oncology drug development and their invaluable insights, along with our diagnostic platform and lab expertise. We are very excited to continue working on developing more innovative diagnostic products and solutions for cancer patients.”

About Genetron’s MRD program in solid tumor and Mutation Capsule technology

Genetron’s MRD program in solid tumor is powered by its Mutation Capsule technology, which was developed in-house and has two distinctive features that are very beneficial in the development of liquid biopsy assays. This proprietary technology allows the detection of methylation alterations and mutations in one reaction, and thus it requires less blood while achieving high detection sensitivity. The second feature is the cell-free DNA (cfDNA) sample’s genetic and epigenetic information can be preserved and amplified in the Mutation Capsule library, and can be used for up to ten analyses without sacrificing sensitivity, enabling significant time and cost savings. In addition to the profiling of different panels of mutation and methylation markers, the library can also be used for low-depth whole genome sequencing to profile genome-wide parameters. It also has the function of de novo discovery of methylation sites that could have diagnostic value.

About Genetron Holdings Limited

Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s plans, strategies and timelines to develop personalized MRD tests for solid tumors in China with AstraZeneca R&D China, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Investor Relations Contact

Hoki Luk
Email: hoki.luk@genetronhealth.com
Phone: +1 (408) 891-9255

Media Relations Contact

Yanrong Zhao
Genetron Health
Email: yanrong.zhao@genetronhealth.com

Genetron Health Reports Third Quarter 2021 Unaudited Financial Results

BEIJING, China, November 30, 2021 — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited preliminary financial results for the third quarter ended September 30, 2021.

Third Quarter and Recent Highlights

- **Financials:**
 - Recorded total revenue of RMB 152.5 million (US \$23.7 million) for the third quarter of 2021, representing a 36.2% increase over the same period of 2020
 - LDT revenue was RMB 93.0 million (US \$14.4 million) in the third quarter of 2021, representing 30.2% growth compared to the prior year period
 - IVD revenue was RMB 51.3 million (US \$8.0 million) in the third quarter of 2021, representing 70.5% growth compared to the prior year period
 - Achieved gross margin of 69.0% for the third quarter 2021 compared to 62.2% in the same period of 2020, primarily driven by improvements in both the LDT and IVD business lines
- **Early screening franchise update:**
 - Genetron has broadened its registrational strategy for its early screening program for hepatocellular carcinoma (HCC). The Company has initiated enrollment for a PCR-based trial in November, with plans to enroll the NGS-based trial in the next few months. Genetron anticipates potential NMPA approvals for both assays in 2023
 - Developed a multi-omics blood-based CRC early screening assay, which was trained in a retrospective cohort of 100 cases and 100 controls, and validated in an independent cohort of the same size. The assay achieved >91% sensitivity with the specificity of 95%. Full details are planned to be released through a publication in 2022
- **MRD franchise update:**
 - Formed a co-development agreement with AstraZeneca R&D China for personalized MRD tests for solid tumors in China. Our partner plans to incorporate the co-developed tests for China-specific studies. This is an exclusive, multi-year collaboration (see detailed release [here](#))
 - Entered into an exclusive agreement with Fosun Pharma to commercialize Seq-MRD® in China, marking the Company’s first product launch for hematologic cancer and MRD detection
- **Publications:**
 - Early Screening: Clinical results and technology findings of Genetron Health’s early liver cancer screening product for hepatocellular carcinoma (HCC), HCCscreen™, were included in an expert consensus and was published in the *Chinese Journal of Hepatology*, an influential publication among liver physicians in China
 - MRD: *Journal of Hematology & Oncology* published an analysis of a personalized MRD assay developed based on Mutation Capsule technology. The assay has shown excellent sensitivity to detect 0.001% tumor DNA from peritoneal lavage fluid samples for precise prediction of peritoneal dissemination in gastric cancer patients
 - Bioinformatics: *Briefings in Bioinformatics* published enhanced variant caller performance data that was achieved by Genetron Health’s bioinformatics team
- **Others:**
 - Established a strategic partnership with NeoGenomics (Nasdaq: NEO) to drive global oncology drug R&D as well as with IMPACT Therapeutics to drive development of a synthetic lethal product pipeline
 - Obtained CE Mark for Onco PanScan™, the Company’s large panel product that covers over 800 genes

“Despite COVID’s impact on our third quarter financial results, we achieved strong year-over-year revenue growth of 36.2%, marked by more than 70% increase in our in-hospital (IVD) sales along with significant gross margin improvement. Operationally, we’ve had many positive updates, which included the initiation of our first registrational trial for HCC early screening, new MRD partnerships, and recognition in multiple influential publications,” remarked Mr. Sizhen Wang, co-founder and CEO of Genetron Health. “Based on the continued enforcement of “zero COVID” strategy in China, we anticipate a significantly tougher operating environment in the fourth quarter. Despite this short-term challenge, we remain laser focused on driving our clinically differentiated pipeline of comprehensive precision oncology diagnostics. Our long-term outlook remains unchanged as we continue to execute on our strategies, and we anticipate multiple data and trial updates from our key programs in the coming months. In addition, the macro environment remains favorable for Genetron, thanks to continued policy tailwinds in China that aim to improve healthcare options for local citizens.”

Third Quarter 2021 Unaudited Preliminary Financial Results

Total revenue for the third quarter of 2021 increased by 36.2% to RMB 152.5 million (US \$23.7 million) from RMB 112.0 million in the same period of 2020.

Diagnosis and monitoring revenue increased by 42.2% to RMB 144.3 million (US \$22.4 million) in the third quarter of 2021 from RMB 101.5 million in the same period of 2020. The increase was primarily driven by the growth in the revenue generated from the sale of both LDT & IVD products.

- Revenue generated from the provision of LDT services increased by 30.2% to RMB 93.0 million (US \$14.4 million) during the third quarter of 2021 from RMB 71.4 million in the same period of 2020, primarily driven by increased sales of HCC early screening tests. LDT diagnostic tests sold in the third quarter 2021 totaled approximately 5,900 units.
- Revenue generated from sales of IVD products increased by 70.5% to RMB 51.3million (US \$8.0 million) in the third quarter of 2021 from RMB 30.1 million in the third quarter of 2020. The increase was driven by sales of the Genetron S5 instrument and 8-gene Lung Cancer Assay (Tissue).

Contracted in-hospital partners (as of the end of the period indicated)

| | 3Q20 | 4Q20 | 1Q21 | 2Q21 | 3Q21 |
|--------------------------------------|------|------|------|------|------|
| IVD In-hospital partners | 20 | 22 | 23 | 28 | 29 |
| Total in-hospital partners(1) | 38 | 40 | 42 | 50 | 54 |

Note:

(1) The number of total in-hospital partners include both sales of LDT services and IVD products.

Revenue generated from development services decreased by 21.4% to RMB 8.2 million (US \$1.3 million) in the third quarter of 2021, from RMB 10.4 million in the same period of 2020. The decrease was mainly due to the decline in sequencing services, as the Company continued to focus on higher margin biopharmaceutical services. Biopharmaceutical revenue continued to grow compared to the same period of 2020.

Gross profit increased by 51.1% to RMB105.2 million (US \$16.3 million) in the third quarter 2021 from RMB 69.6 million in the same period of 2020. Gross margin improved to 69.0% for the third quarter of 2021, compared to 62.2% in the same period of 2020, primarily due to higher gross margins for both the LDT and IVD business lines.

Selling expenses increased by 56.3% to RMB 94.6 million (US \$14.7 million) in the third quarter of 2021 from RMB 60.6 million in the same period of 2020. Selling expenses as a percentage of revenues was 62.0% in the third quarter of 2021, compared to 54.1% in the same period of 2020. The increase was primarily driven by increased headcount to expand Genetron's core business as well as early screening sales teams.

Administrative expenses increased by 94.1% to RMB 63.0 million (US \$9.8 million) in the third quarter of 2021 from RMB 32.4 million in the same period of 2020. Administrative expenses as a percentage of revenues increased to 41.3% in the third quarter of 2021 from 29.0% in the third quarter of 2020. The increase was mainly driven by higher headcount, professional fees, IT expenses, and share-based compensation.

Research and development expenses increased by 61.7% to RMB 62.4 million (US \$9.7 million) in the third quarter of 2021 from RMB 38.6 million in the same period of 2020. Research and development expenses as a percentage of revenues increased to 40.9% in the third quarter of 2021 from 34.4% in the same period of 2020. The increases were driven by higher R&D headcount and related expenses, as well as continued innovation efforts, including product development and clinical trial activities.

Loss for the period was RMB 130.1 million (US \$20.2 million) for the three months ended September 30, 2021, compared to RMB 48.0 million for the three months ended September 30, 2020.

Non-IFRS loss for the period, defined as loss for the period excluding share-based compensation expenses, fair value change and other loss of financial instruments with preferred rights, was RMB109.9 million (US \$17.1 million) for the three months ended September 30, 2021, compared to RMB 43.7 million for the three months ended September 30, 2020. Please refer to the section in this press release titled "Non-IFRS Financial Measures" for details.

Basic loss per share attributable to ordinary shareholders of the Company was RMB 0.28 (US \$0.04) for the third quarter of 2021, compared with a basic loss per share attributable to ordinary shareholders of the Company of RMB 0.11 for the same period of 2020.

Excluding share-based compensation expenses, fair value change of financial instruments with preferred rights and other loss of financial instruments with preferred rights, non-IFRS basic loss per share attributable to ordinary shareholders of the Company was RMB 0.24 (US \$0.04) for the third quarter of 2021, compared with non-IFRS basic loss per share attributable to ordinary shareholders of the Company of RMB 0.10 for the same period of 2020.

Diluted loss per share attributable to ordinary shareholders of the Company is equivalent to basic loss per share attributable to ordinary shareholders of the Company. Each ADS represents of five ordinary shares, par value US \$0.00002 per share. Please refer to the section in this press release titled “Non-IFRS Financial Measures” for details.

As of September 30, 2021, cash and cash equivalents, restricted cash and current financial assets at fair value through profit or loss were RMB 1,005.3 million (US \$156.0 million).

2021 Financial Guidance

Based on the continued enforcement of the “zero COVID” strategy in China and the resulting sustained restrictions across Genetron’s major markets, the Company is revising its full year 2021 revenue guidance to be around RMB 530 million, representing approximately 24.9% growth over the Company’s full year 2020 revenue.

Conference Call

A conference call and webcast to discuss the results will be held at 8:30 a.m. U.S. Eastern Time on November 30, 2021 (or at 9:30 p.m. Beijing Time on November 30, 2021). Interested parties may listen to the conference call by dialing numbers below:

| | |
|-----------------|-----------------|
| United States: | +1-332-208-9468 |
| China Domestic: | 400-820-5286 |
| Hong Kong: | +852-3018-6771 |
| International: | +65-6713-5590 |
| Conference ID: | 5848053 |

Participants are encouraged to dial into the call at least 15 minutes in advance due to high call volumes.

A replay will be accessible through December 7, 2021 by dialing the following numbers:

| | |
|----------------|-----------------|
| United States: | +1-855-452-5696 |
| International: | +61-2-8199-0299 |
| Conference ID: | 5848053 |

A simultaneous webcast of the conference call will be available on the “News and Presentations” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit ir.genetronhealth.com.

Exchange Rate Information

All translations made in the financial statements or elsewhere in this press release made from RMB into United States dollars (“US\$”) are solely for convenience and calculated at the rate of US\$1.00=RMB 6.4434, representing the exchange rate as of September 30, 2021, set forth in the H.10 statistical release of the U.S. Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US\$ at that rate, or at any other rate, on September 30, 2021.

Non-IFRS Financial Measures

The Company uses non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period, which are non-IFRS financial measures, in evaluating its operating results and for financial and operational decision-making purposes. The Company believes that non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company help identify underlying trends in the Company's business that could otherwise be distorted by the effect of certain expenses that the Company includes in its loss for the year/period. The Company believes that non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period provide useful information about its results of operations, enhances the overall understanding of its past performance and future prospects and allows for greater visibility with respect to key metrics used by its management in its financial and operational decision-making.

Non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period should not be considered in isolation or construed as an alternative to operating profit, loss for the year/period or any other measure of performance or as an indicator of its operating performance. Investors are encouraged to review non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period and the reconciliation to its most directly comparable IFRS measures. Non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to the Company's data. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure.

Non-IFRS loss and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period represent loss for the year/period excluding share-based compensation expenses, fair value change of financial instruments with preferred rights and other loss of financial instruments with preferred rights (if applicable).

Please see the "Unaudited Non-IFRS Financial Measures" included in this press release for a full reconciliation of non-IFRS loss for the year/period to loss for the year/period and non-IFRS loss per share attributable to ordinary shareholders of the Company for the year/period to loss per share attributable to ordinary shareholders of the Company for the year/period.

About Genetron Holdings Limited

Genetron Holdings Limited ("Genetron Health" or the "Company") (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as "may", "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Investor Relations Contact**US:**

Hoki Luk
Head of Investor Relations
Email: hoki.luk@genetronhealth.com
Phone: +1 (408) 891-9255

Philip Trip Taylor
Vice President | Gilmartin Group
ir@genetronhealth.com

Media Relations Contact

Yanrong Zhao
Genetron Health
yanrong.zhao@genetronhealth.com

Edmond Lococo
ICR
Edmond.Lococo@icrinc.com
Mobile: +86 138-1079-1408
genetron.pr@icrinc.com

GENETRON HOLDINGS LIMITED
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF LOSS

| | For the three months ended | | | For the nine months ended | | |
|--|----------------------------------|-------------------------------|-------------|----------------------------------|-------------------------------|-------------|
| | September 30, 2020 RMB'000 | September 30, 2021 RMB'000 | US\$'000 | September 30, 2020 RMB'000 | September 30, 2021 RMB'000 | US\$'000 |
| Revenue | 111,963 | 152,541 | 23,674 | 290,541 | 385,087 | 59,765 |
| Cost of revenue | (42,331) | (47,306) | (7,342) | (114,448) | (130,839) | (20,306) |
| Gross profit | 69,632 | 105,235 | 16,332 | 176,093 | 254,248 | 39,459 |
| Selling expenses | (60,558) | (94,625) | (14,686) | (175,000) | (242,812) | (37,684) |
| Administrative expenses | (32,440) | (62,981) | (9,774) | (81,969) | (162,161) | (25,167) |
| Research and development expenses | (38,556) | (62,364) | (9,679) | (96,030) | (168,500) | (26,151) |
| Net impairment losses on financial and contract assets | (1,107) | (10,437) | (1,620) | (2,097) | (23,741) | (3,684) |
| Other income/(loss) - net | 3,819 | 334 | 52 | (513) | 8,945 | 1,388 |
| Operating expenses | (128,842) | (230,073) | (35,707) | (355,609) | (588,269) | (91,298) |
| Operating loss | (59,210) | (124,838) | (19,375) | (179,516) | (334,021) | (51,839) |
| Finance income | 12,772 | 482 | 75 | 11,062 | 1,712 | 265 |
| Finance costs | (1,560) | (5,791) | (898) | (3,997) | (5,022) | (779) |
| Finance income/(costs) - net | 11,212 | (5,309) | (823) | 7,065 | (3,310) | (514) |
| Fair value loss of financial instruments with preferred rights | — | — | — | (2,823,370) | — | — |
| Loss before income tax | (47,998) | (130,147) | (20,198) | (2,995,821) | (337,331) | (52,353) |
| Income tax expense | — | — | — | — | — | — |
| Loss for the period | (47,998) | (130,147) | (20,198) | (2,995,821) | (337,331) | (52,353) |
| Loss attributable to: | | | | | | |
| Owners of the Company | (47,998) | (128,974) | (20,016) | (2,995,821) | (333,548) | (51,766) |
| Non-controlling interests | — | (1,173) | (182) | — | (3,783) | (587) |
| | (47,998) | (130,147) | (20,198) | (2,995,821) | (337,331) | (52,353) |
| Loss per share attributable to ordinary shareholders of the Company | RMB | RMB | USD | RMB | RMB | USD |
| -Basic and diluted | (0.11) | (0.28) | (0.04) | (12.02) | (0.73) | (0.11) |
| Loss per ADS attributable to ordinary shareholders of the Company | | | | | | |
| -Basic and diluted | (0.53) | (1.40) | (0.22) | (60.10) | (3.63) | (0.56) |
| Shares used in loss per share attributable to ordinary shareholders of the Company computation: | | | | | | |
| -Basic and diluted | 454,231,486 | 461,356,043 | 461,356,043 | 249,230,922 | 459,793,465 | 459,793,465 |
| ADS used in loss per ADS attributable to ordinary shareholders of the Company computation: | | | | | | |
| -Basic and diluted | 90,846,297 | 92,271,209 | 92,271,209 | 49,846,184 | 91,958,693 | 91,958,693 |

GENETRON HOLDINGS LIMITED

UNAUDITED NON-IFRS FINANCIAL MEASURE

| | For the three months ended | | | For the nine months ended | | |
|---|----------------------------------|---|-----------------|----------------------------------|---|-----------------|
| | September 30, 2020 RMB'000 | September 30, 2021 RMB'000 US\$'000 | | September 30, 2020 RMB'000 | September 30, 2021 RMB'000 US\$'000 | |
| Loss for the period | (47,998) | (130,147) | (20,198) | (2,995,821) | (337,331) | (52,353) |
| Adjustments: | | | | | | |
| Share-based compensation | 4,268 | 20,246 | 3,141 | 19,222 | 42,000 | 6,518 |
| Fair value loss of financial instruments with preferred rights | — | — | — | 2,823,370 | — | — |
| Non-IFRS Loss | <u>(43,730)</u> | <u>(109,901)</u> | <u>(17,057)</u> | <u>(153,229)</u> | <u>(295,331)</u> | <u>(45,835)</u> |
| Attributable to: | | | | | | |
| Owners of the Company | (43,730) | (108,728) | (16,875) | (153,229) | (291,548) | (45,248) |
| Non-controlling interests | — | (1,173) | (182) | — | (3,783) | (587) |
| | <u>(43,730)</u> | <u>(109,901)</u> | <u>(17,057)</u> | <u>(153,229)</u> | <u>(295,331)</u> | <u>(45,835)</u> |
| Non-IFRS loss per share attributable to ordinary shareholders of the Company | RMB | RMB | USD | RMB | RMB | USD |
| -Basic and diluted | <u>(0.10)</u> | <u>(0.24)</u> | <u>(0.04)</u> | <u>(0.61)</u> | <u>(0.63)</u> | <u>(0.10)</u> |
| Non-IFRS loss per ADS(5 ordinary shares equal to 1 ADS) attributable to ordinary shareholders of the Company | | | | | | |
| -Basic and diluted | <u>(0.48)</u> | <u>(1.18)</u> | <u>(0.18)</u> | <u>(3.07)</u> | <u>(3.17)</u> | <u>(0.49)</u> |
| Shares used in non-IFRS loss per share attributable to ordinary shareholders of the Company computation: | | | | | | |
| -Basic and diluted | 454,231,486 | 461,356,043 | 461,356,043 | 249,230,922 | 459,793,465 | 459,793,465 |
| ADS used in non-IFRS loss per ADS attributable to ordinary shareholders of the Company computation: | | | | | | |
| -Basic and diluted | 90,846,297 | 92,271,209 | 92,271,209 | 49,846,184 | 91,958,693 | 91,958,693 |

GENETRON HOLDINGS LIMITED
UNAUDITED REVENUE AND SEGMENT INFORMATION

| | Diagnosis and monitoring - provision of LDT services RMB'000 | Diagnosis and monitoring - sale of IVD products RMB'000 | Development services RMB'000 | Total RMB'000 |
|--|--|---|------------------------------------|------------------|
| Three months ended September 30, 2020 | | | | |
| Revenue | 71,406 | 30,110 | 10,447 | 111,963 |
| Segment profit | 49,212 | 18,439 | 1,981 | 69,632 |
| Three months ended September 30, 2021 | | | | |
| Revenue | 92,993 | 51,338 | 8,210 | 152,541 |
| Segment profit | 65,022 | 39,159 | 1,054 | 105,235 |
| Nine months ended September 30, 2020 | | | | |
| Revenue | 194,754 | 67,468 | 28,319 | 290,541 |
| Segment profit | 130,961 | 43,827 | 1,305 | 176,093 |
| Nine months ended September 30, 2021 | | | | |
| Revenue | 251,959 | 110,431 | 22,697 | 385,087 |
| Segment profit | 175,723 | 75,693 | 2,832 | 254,248 |

GENETRON HOLDINGS LIMITED

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

| | <u>As at December 31,2020</u> | <u>As at September 30,2021</u> | |
|---|-------------------------------|--------------------------------|----------------|
| | RMB'000 | RMB'000 | US\$'000 |
| ASSETS | | | |
| Non-current assets | | | |
| Property, plant and equipment | 76,891 | 85,441 | 13,260 |
| Right-of-use assets | 59,706 | 50,938 | 7,905 |
| Intangible assets | 12,265 | 15,104 | 2,344 |
| Financial assets at fair value through profit or loss | 19,609 | 37,005 | 5,743 |
| Prepayments | 15,362 | 23,765 | 3,688 |
| Total non-current assets | <u>183,833</u> | <u>212,253</u> | <u>32,940</u> |
| Current assets | | | |
| Inventories | 24,971 | 41,657 | 6,465 |
| Contract assets | 1,112 | 2,217 | 344 |
| Other current assets | 36,500 | 26,513 | 4,115 |
| Trade receivables | 164,592 | 279,725 | 43,413 |
| Other receivables and prepayments | 42,420 | 83,188 | 12,911 |
| Amounts due from related parties | 214 | 453 | 70 |
| Financial assets at fair value through profit or loss | 140,294 | 187,398 | 29,084 |
| Derivative financial instruments | 196 | 673 | 104 |
| Restricted cash | — | 2,800 | 435 |
| Cash and cash equivalents | 1,375,766 | 815,142 | 126,508 |
| Total current assets | <u>1,786,065</u> | <u>1,439,766</u> | <u>223,449</u> |
| Total assets | <u>1,969,898</u> | <u>1,652,019</u> | <u>256,389</u> |

GENETRON HOLDINGS LIMITED

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)

| | <u>As at December 31, 2020</u> | <u>As at September 30, 2021</u> | |
|---|--------------------------------|---------------------------------|----------------|
| | RMB'000 | RMB'000 | US\$'000 |
| LIABILITIES | | | |
| Non-current liabilities | | | |
| Borrowings | 5,493 | — | — |
| Lease liabilities | 43,016 | 32,694 | 5,074 |
| Other non-current liabilities | — | 8,354 | 1,297 |
| Total non-current liabilities | <u>48,509</u> | <u>41,048</u> | <u>6,371</u> |
| Current liabilities | | | |
| Trade payables | 34,071 | 38,907 | 6,038 |
| Contract liabilities | 8,417 | 12,640 | 1,962 |
| Other payables and accruals | 111,164 | 119,399 | 18,530 |
| Amounts due to related parties | 24 | 350 | 54 |
| Borrowings | 58,583 | 27,595 | 4,283 |
| Lease liabilities | 16,585 | 19,640 | 3,048 |
| Derivative financial instruments | — | 1,702 | 264 |
| Total current liabilities | <u>228,844</u> | <u>220,233</u> | <u>34,179</u> |
| Total liabilities | <u>277,353</u> | <u>261,281</u> | <u>40,550</u> |
| Net assets | <u>1,692,545</u> | <u>1,390,738</u> | <u>215,839</u> |
| SHAREHOLDERS' EQUITY | | | |
| Equity attributable to owners of the Company | | | |
| Share capital | 59 | 60 | 9 |
| Share premium | 6,657,562 | 6,702,347 | 1,040,188 |
| Other reserves | (24,701) | (44,784) | (6,950) |
| Accumulated losses | (4,940,375) | (5,273,923) | (818,500) |
| | <u>1,692,545</u> | <u>1,383,700</u> | <u>214,747</u> |
| Non-controlling interests | <u>—</u> | <u>7,038</u> | <u>1,092</u> |
| Total shareholders' equity | <u>1,692,545</u> | <u>1,390,738</u> | <u>215,839</u> |